Corona Remedies Ltd

CORONA Remedies Limited will hold a board meeting on Friday, October 30, 2026, to consider and approve the unaudited financial results (standalone and consolidated) for the second quarter and half year ended September 30, 2026, and other business matters. The trading window for dealing in the company's securities will remain closed until Sunday, November 01, 2026, as previously communicated on September 28, 2026.

Corona Remedies Limited informed the BSE Limited and National Stock Exchange of India that Bigshare Services Private Limited, the company's Registrar to Issue and Share Transfer Agent, has confirmed the non-applicability of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, as all shares are held in demat form and no requests for rematerialization or dematerialization were received.

Corona Remedies Ltd announced credit rating actions from multiple agencies, with CARE Rating Limited reaffirming the rating for Long Term Bank Facilities at CARE A+; Stable, previously at 25.00, and upgrading Long-Term / Short-Term Bank Facilities from CARE A+; Stable / CARE A1 to CARE A+; Stable / CARE A1+, while CARE Ratings Ltd. mirrored the reaffirmation and upgrade; additionally, CARE Ratings Ltd. assigned a BBB+ rating to Term Loan Facilities amounting to 100 crore, and noted the possibility of annual surveillance/review, along with continuous monitoring for certain bank facilities, though incomplete data prevents full rating information; CareEdge Ratings provided a rating reflecting opinions as on the date of the rating, without specifying instruments or amounts, and the text also indicates an awaiting full text related to dissemination of information, alongside noting that no rating data was found and that the issuer is not cooperating for another facility.

CORONA Remedies Limited informed the BSE Limited and National Stock Exchange of India Limited that the trading window for dealing in the company's securities will be closed from October 01, 2026, until 48 hours after the declaration of the unaudited financial results for the second quarter and half year ending September 30, 2026, in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.

Corona Remedies Ltd share price inched up 0.38% to Rs 2097.6 after the company's net profit soared by 32.61% to Rs 60.11 crore, while revenue from operations gained 19.64% to Rs 422.43 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 23.86 lakh crore, easing 5.89%. It has marginally improved by 2.79% over last one week and jumped by 15.59% in last one month while the market capitalization of Corona Remedies Ltd has softened by 0.78% and 21.60% in the same period respectively. Profit before tax (PBT) of Corona Remedies Ltd stood at Rs 80.36 crore in Q2 FY26, jumping 32.41% year-on-year, and expanding by 46.80% quarter-on-quarter. EBITDA came in at Rs 90 crore, surging by 32.79% YoY and rallying 55.38% sequentially. Total expenses advancing by 13.66% to Rs 342.54 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 32.65 crore, increasing 17.74% YoY, while employee benefits expense was at Rs 122.09 crore, witnessing a strong rise of 14.50% YoY. For the TTM ended FY26, revenue from operations grew 17.28% to Rs 1403.18 crore, while net profit jumped 23.88% to Rs 185.12 crore, compared to previous TTM. EBITDA jumped by 23376% to Rs 282.79 crore, and PBT soared 21.10% to Rs 240.42 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 229.48 crore in FY26, as against Rs 190.5 crore in FY25. Corona Remedies Ltd surged by 45.95% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 3.81% during the same period.

Corona Remedies Ltd share price softened by 0.77% to Rs 2089.65. The Company's net profit soared by 32.61% to Rs 60.11 crore, while revenue from operations gained 19.64% to Rs 422.43 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 23.86 lakh crore, easing 6%. It has inched up 2.79% over last one week and surged by 15.59% in last one month while the market capitalization of Corona Remedies Ltd has slipped by 0.78% and 21.60% in the same period respectively. Profit before tax (PBT) of Corona Remedies Ltd stood at Rs 80.36 crore in Q2 FY26, surging by 32.41% year-on-year, and rallying 46.80% quarter-on-quarter. EBITDA came in at Rs 90 crore, expanding by 32.79% YoY and jumping 55.38% sequentially. Total expenses increased by 13.66% to Rs 342.54 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 32.65 crore, advancing by 17.74% YoY, while employee benefits expense was at Rs 122.09 crore, witnessing a strong rise of 14.50% YoY. For the TTM ended FY26, revenue from operations grew 17.28% to Rs 1403.18 crore, while net profit saw a strong growth of 23.88% to Rs 185.12 crore, compared to previous TTM. EBITDA surged by 23376% to Rs 282.79 crore, and PBT surged 21.10% to Rs 240.42 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 229.48 crore in FY26, as against Rs 190.5 crore in FY25. Corona Remedies Ltd rallied 45.40% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 4.36% during the same period.

CORONA Remedies Limited announced its unaudited financial results for the first quarter of fiscal year 2027, reporting revenue of Rs 422.4 crore, a 21.9% year-over-year increase, and profit after tax of Rs 60.1 crore, a 30.1% year-over-year increase. The company, a leading India-focused branded pharmaceutical company, also inaugurated a European Union Good Manufacturing Practice (EU-GMP) approved Female Hormone Manufacturing Facility in Ahmedabad and initiated the integration of the acquired brand, Wokadine.

Corona Remedies will hold a meeting of the Board of Directors of the Company on 31 July 2026.

Corona Remedies announced that the 22th Annual General Meeting(AGM) of the company will be held on 9 July 2026.

Corona Remedies announced that the Board of Directors of the Company at its meeting held on 11 May 2026, inter alia, have recommended the final dividend of Rs 10 per equity Share (i.e. 100%) , subject to the approval of the shareholders.